The Health Resources and Services Administration today released a proposed rule that would implement an Affordable Care Act provision requiring a binding administrative dispute resolution process for 340B Drug Pricing Program participants who claim they have been overcharged for drugs purchased through the program. Under the proposed process, which also would be available to drug manufacturers, a decision-making body within the Department of Health and Human Services would review and resolve the claims. The proposed rule will be published in the Aug. 12 Federal Register with comments accepted through Oct. 11. AHA staff are reviewing the rule, and member hospitals that are 340B participants will receive more information.

Related News Articles

Headline
The Centers for Medicare & Medicaid Services July 16 released its final guidance on the Medicare Prescription Payment Plan which will begin next year. The…
Headline
The AHA July 11 released its quarterly Health Care Plan Accountability Update, a roundup of news, letters, statements and other resources covering private…
Headline
The AHA submitted a statement July 11 for a Senate Special Committee on Aging hearing on health care transparency and lowering health care costs. The AHA…
Headline
The AHA, 340B Health, Maryland Hospital Association and Mid-Atlantic Association of Community Health Centers July 9 filed an amicus brief in a federal district…
Headline
The Centers for Medicare & Medicaid Services July 10 issued a proposed rule that would increase Medicare hospital outpatient prospective payment system…
Headline
The Healthcare Equality Network July 3 sent a letter to the Centers for Medicare & Medicaid Services, expressing concerns about claims denials by…